What is the first-line antibiotic for a hospitalized patient with a urinary tract infection caused by Enterococcus faecalis?

First-Line Antibiotic for Enterococcus faecalis UTI in Hospitalized Patients

For a hospitalized patient with urinary tract infection caused by Enterococcus faecalis, ampicillin is the first-line antibiotic of choice, provided the organism is susceptible. 1

Treatment Algorithm

Step 1: Determine Susceptibility Status

The critical first step is obtaining susceptibility testing, as E. faecalis resistance patterns vary significantly:

• If ampicillin-susceptible: Use ampicillin as first-line therapy
• If ampicillin-resistant but vancomycin-susceptible: Use vancomycin
• If vancomycin-resistant (VRE): See alternative regimens below

Step 2: Select Appropriate Regimen

For Ampicillin-Susceptible E. faecalis (Most Common)

High-dose ampicillin 18-30 g IV daily in divided doses or amoxicillin 500 mg IV every 8 hours 1. This remains the gold standard because:

• E. faecalis is typically ampicillin-susceptible (unlike E. faecium) 2
• High urinary concentrations can overcome even elevated MICs 1
• One retrospective study showed 88.1% clinical cure and 86% microbiological eradication even in ampicillin-resistant VRE UTIs when treated with ampicillin 1
• All enterococcal isolates in a prospective UK study remained ampicillin-sensitive 3

For Vancomycin-Resistant E. faecalis (VRE)

The 2022 guidelines provide a clear hierarchy 1:

1. Fosfomycin 3 g PO single dose - for uncomplicated UTI (weak recommendation, 2D)
2. Nitrofurantoin 100 mg PO every 6 hours - for uncomplicated UTI (weak recommendation, 2D)
3. High-dose ampicillin (as above) - even for VRE UTI (weak recommendation, 2D)
4. Linezolid 600 mg IV or PO every 12 hours - for more serious enterococcal infections (strong recommendation, 1C) 1

Step 3: Duration of Therapy

• 7-14 days for complicated UTI 4
• 14 days for men when prostatitis cannot be excluded 4
• Duration should be tailored to clinical response and resolution of underlying abnormalities

Critical Pitfalls to Avoid

1. Do Not Use Ciprofloxacin Empirically

Fluoroquinolone resistance in E. faecalis is alarmingly high:

• 46-47% resistance to levofloxacin/ciprofloxacin in Korean study 5
• 58% resistance to norfloxacin 5
• Resistance increases with age: 22% in young adults to 37% in elderly 6
• Ciprofloxacin is no longer recommended for E. faecalis UTI 5

The EAU 2024 guidelines explicitly state: "Do not use ciprofloxacin and other fluoroquinolones for empirical treatment of complicated UTI in patients from urology departments" 4

2. Distinguish Between Colonization and True Infection

This is particularly important in hospitalized patients with catheters 1. E. faecalis is frequently isolated but may represent colonization rather than infection, especially in polymicrobial cultures (47% of cases) 6.

3. Consider Recurrence Risk

E. faecalis UTIs have significantly higher recurrence rates than E. coli:

• 26% vs 22% overall recurrence 6
• Increases from 12% in young adults to 28% in elderly 6
• This emphasizes the importance of treating underlying urological abnormalities 4

Special Considerations for Hospitalized Patients

Catheter-Associated UTI

For CA-UTI with E. faecalis, treat according to complicated UTI recommendations 4:

• Combination therapy: Amoxicillin plus aminoglycoside OR second-generation cephalosporin plus aminoglycoside 4
• However, note that enterococci have intrinsic resistance to cephalosporins, so ampicillin-based regimens are preferred

When Linezolid May Be Preferred

A 2024 French multicenter study of 81 patients with enterococcal UTI treated with linezolid showed 7:

• 97.5% treatment success rate
• Median treatment duration 13 days
• Only 3 adverse events, none serious
• Effective even when prior empiric therapy failed

Linezolid 600 mg IV or PO every 12 hours carries a strong recommendation (1C) for enterococcal infections 1, making it a reasonable first-line choice when:

• VRE is suspected or confirmed
• Patient cannot tolerate β-lactams
• Prior ampicillin therapy has failed

Emerging Options

Recent data show promise for newer agents 8, 9:

• Fosfomycin: 95-96% susceptibility against E. faecalis, effective against ESBL producers
• Gepotidacin: MIC90 of 4 µg/mL for E. faecalis, 94% bactericidal activity

Evidence Quality Assessment

The strongest evidence comes from the 2022 multidrug-resistant organism guidelines 1, which provide systematic recommendations despite acknowledging low-quality evidence (most recommendations are 2C or 2D). The 2015 AHA endocarditis guidelines 2 provide additional context for serious enterococcal infections, though focused on endocarditis rather than UTI. The 2024 EAU guidelines 4 offer the most recent guidance on complicated UTI management.

The key clinical takeaway: Start with ampicillin for susceptible E. faecalis, avoid fluoroquinolones entirely, and use linezolid for VRE or when β-lactams fail.